OKYO Pharma Limited Announces final audited results for the year ended 31 March 2021
02. August 2021 06:57 ET
|
OKYO Pharma LTD
LONDON, Aug. 02, 2021 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (the “Company”) is pleased to announce its final audited results for the year ended 31 March 2021. Summary of OKYO-101 studies during...
("OKYO" or the "Company") - OKYO Pharma Retains Ora Inc. to Perform Regulatory Development of OK-101 for Dry Eye Indications
29. Juni 2021 08:14 ET
|
OKYO Pharma LTD
LONDON and BOSTON, June 29, 2021 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (LSE: OKYO; OTCQB: EMMLF), a biotechnology company focused on the discovery and development of novel molecules to treat...
("OKYO" or the "Company") - OKYO Pharma Announces Positive Data and Results in an Animal Model using Topically Administered OK-201 to Treat Neuropathic Ocular Pain
28. April 2021 02:00 ET
|
OKYO Pharma LTD
LONDON and BOSTON, April 28, 2021 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (LSE: OKYO; OTCQB: EMMLF), a biotechnology company focused on the discovery and development of novel molecules to treat...
OKYO Pharma Limited ("OKYO" or the "Company") - OKYO announces appointment of Dr Rajkumar Patil as Chief Scientific Officer
29. März 2021 02:00 ET
|
OKYO Pharma LTD
LONDON, March 29, 2021 (GLOBE NEWSWIRE) -- OKYO (LSE: OKYO; OTCQB: EMMLF), the life sciences and biotechnology company focused on the discovery and development of novel molecules to treat...
OKYO Pharma Limited ("OKYO" or the "Company") - Issue of Equity
01. März 2021 02:00 ET
|
OKYO Pharma LTD
LONDON, March 01, 2021 (GLOBE NEWSWIRE) -- OKYO Pharma Limited ("OKYO" or the "Company") today announces that it has issued 250,000 ordinary shares of no par value ("Ordinary Shares"), credited as...
OKYO Pharma has U.S. Patent Issued Covering its Lipid Conjugated Peptide Analogues for treating Ocular Pain and Inflammation
23. Februar 2021 02:00 ET
|
OKYO Pharma LTD
LONDON, Feb. 23, 2021 (GLOBE NEWSWIRE) -- OKYO Pharma Limited ("OKYO" or the "Company"), a biotechnology company focused on the development of novel drugs to treat inflammatory eye diseases and...
OKYO Pharma Limited ("OKYO" or the "Company") - OKYO announces filing of a patent application covering the use of Chemerin and associated analogues to treat “cytokine storm” associated with COVID-19 and ARDS
19. Januar 2021 02:00 ET
|
OKYO Pharma LTD
LONDON and BOSTON, Jan. 19, 2021 (GLOBE NEWSWIRE) -- OKYO (LSE: OKYO; OTCQB: EMMLF), the life sciences and biotechnology company focused on the discovery and development of novel molecules to treat...
OKYO Pharma Limited ("OKYO" or the "Company") - Result of the Annual General Meeting
25. September 2020 07:00 ET
|
OKYO Pharma LTD
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF REGULATION (EU) NO 596/2014 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM...
Notice of Annual General Meeting
09. September 2020 02:00 ET
|
OKYO Pharma LTD
LONDON, Sept. 09, 2020 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (LSE: OKYO), the life sciences and biotechnology company focused on the discovery and development of novel molecules to treat...
OKYO Pharma Limited ("OKYO" or the "Company") - Appointment of Dr. Napoleone Ferrara to Serve on Its Scientific Advisory Board
19. August 2020 02:00 ET
|
OKYO Pharma LTD
LONDON, Aug. 19, 2020 (GLOBE NEWSWIRE) -- OKYO, the life sciences and biotechnology company, focused on the discovery and development of novel molecules to treat inflammatory dry eye diseases and...